A Few Companies Are Reaping The Benefits Of NIH Investigator-Initiated Basic Grants

Investigator-Initiated Basic Grants Author: Lee Katterman At a time when biotechnology and some pharmaceutical companies are working hard to finance research and product development, a small number of firms are tapping a pot of federal money generally thought to support only projects led by academic scientists. Some industry officials value this source of support for studies a company might not otherwise be able to afford, while others avoid it because of the strings that come with it. SEPAR

Lee Katterman
Nov 26, 1995

Investigator-Initiated Basic Grants Author: Lee Katterman

At a time when biotechnology and some pharmaceutical companies are working hard to finance research and product development, a small number of firms are tapping a pot of federal money generally thought to support only projects led by academic scientists. Some industry officials value this source of support for studies a company might not otherwise be able to afford, while others avoid it because of the strings that come with it.

James Paulson SEPARATE REALMS: James Paulson of Cytel Corp. takes pains to differentiate his grant-related and company projects. The money in question comes from the nearly $4 billion awarded annually by the National Institutes of Health to support the thousands of individual, curiosity-driven research projects proposed by scientists and physicians. These funds are disbursed via "traditional" research grants-known as "R01s," after the prefix attached to each grant identification number- that pay for the basic...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?